Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS).
Phase of Trial: Phase IV
Latest Information Update: 10 Dec 2013
At a glance
- Drugs Alefacept (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Acronyms ATLAS
- 07 Mar 2012 Actual patient number (1897) added as reported by ClinicalTrials.gov
- 07 Mar 2012 Planned end date changed from 1 Dec 2025 to 1 Jan 2012 as reported by ClinicalTrials.gov
- 07 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.